Arabic Arabic English English French French German German
dark

Using personalized medicine to avoid resistance to leukemia treatment

T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Everest launches rebrand of sports and entertainment division

Next Post

AZ’s Farxiga scores US approval in chronic kidney disease

Related Posts
Total
0
Share